A BCR::ABL1 exon 13 variant leads to systematic underestimation of transcript level in the molecular monitoring of CML

Key Points

• Underestimation of transcript levels impacts molecular monitoring in chronic myeloid leukemia (CML), leading to potential misinterpretations.
• The BCR::ABL1 exon 13 variant shows significant discrepancies in transcript detection, affecting clinical outcomes.
• Analysis conducted on patient samples reveals consistent underestimation linked to the exon 13 variant.
• Highlights the need for updated molecular monitoring strategies to improve CML management and treatment outcomes.